(Q36115235)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

title

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

main subject

phase II clinical trial

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

M Middleton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

L Ashcroft

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

N Thatcher

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

language of work or name

English

0 references

publication date

1 August 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

2 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

page(s)

366-369

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

Medical treatment of advanced renal cell carcinoma: present options and future directions

2 December 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063040

Combination therapy with subcutaneous interleukin-2 and interferon-alpha in advanced renal cancer patients with poor prognostic factors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063040

Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063040

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063040

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063040

alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063040

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063040

Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063040

Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells

23 September 2018

1 reference

12 December 2020

Immunotherapy of metastatic renal cell cancer

1 reference

12 December 2020

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

12 December 2020

Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2

1 reference

12 December 2020

A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Interferon-alpha and survival in renal cell cancer

1 reference

12 December 2020

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.500

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

PubMed publication ID

9703284

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9703284%20AND%20SRC:MED&resulttype=core&format=json